Compositions, formulations and methods for treating ocular diseases

Abstract

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.

1 - 54 . (canceled) 
     
     
         55 . A method of treating glaucoma, the method comprising administering to a subject in need thereof a therapeutically-effective amount of a Tie-2 activator, or a pharmaceutically-acceptable salt thereof. 
     
     
         56 . The method of  claim 55 , wherein the Tie-2 activator or the pharmaceutically-acceptable salt thereof binds HPTP-beta. 
     
     
         57 . The method of  claim 55 , wherein the Tie-2 activator or the pharmaceutically-acceptable salt thereof inhibits HPTP-beta. 
     
     
         58 . The method of  claim 55 , wherein the Tie-2 activator or the pharmaceutically-acceptable salt thereof is a phosphate mimetic. 
     
     
         59 . The method of  claim 55 , wherein the Tie-2 activator or the pharmaceutically-acceptable salt thereof comprises an amino acid backbone. 
     
     
         60 . The method of  claim 55 , wherein the Tie-2 activator or the pharmaceutically-acceptable salt thereof comprises a sulfamic acid. 
     
     
         61 . The method of  claim 55 , wherein the Tie-2 activator or the pharmaceutically-acceptable salt thereof is administered subcutaneously. 
     
     
         62 . The method of  claim 55 , wherein the Tie-2 activator or the pharmaceutically-acceptable salt thereof is administered topically. 
     
     
         63 . The method of  claim 55 , wherein the Tie-2 activator or the pharmaceutically-acceptable salt thereof is administered to an eye of the subject. 
     
     
         64 . The method of  claim 55 , wherein the Tie-2 activator or the pharmaceutically-acceptable salt thereof is formulated as a drop. 
     
     
         65 . The method of  claim 55 , wherein the Tie-2 activator or the pharmaceutically-acceptable salt thereof is formulated as a drop, wherein the drop is administered to an eye of the subject. 
     
     
         66 . The method of  claim 55 , wherein the therapeutically-effective amount is from about 0.1 mg to about 100 mg. 
     
     
         67 . The method of  claim 55 , wherein the therapeutically-effective amount is from about 0.5 mg to about 30 mg. 
     
     
         68 . The method of  claim 55 , wherein the therapeutically-effective amount is from about 0.05 mg to about 1.5 mg. 
     
     
         69 . The method of  claim 55 , wherein the therapeutically-effective amount is about 0.05 mg. 
     
     
         70 . The method of  claim 55 , wherein the therapeutically-effective amount is about 30 mg. 
     
     
         71 . The method of  claim 55 , wherein the therapeutically-effective amount is about 15 mg. 
     
     
         72 . The method of  claim 55 , wherein the subject is human.